Gain Therapeutics, Inc. (GANX)
After hours:
| Previous Close | 1.6200 |
| Open | 1.6096 |
| Bid | 1.6700 x 100 |
| Ask | 1.7600 x 100 |
| Day's Range | 1.5855 - 1.7800 |
| 52 Week Range | 0.8900 - 5.3300 |
| Volume | |
| Avg. Volume | 388,129 |
| Market Cap | 45.623M |
| Beta (5Y Monthly) | 0.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0700 |
| Earnings Date | Nov 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.40 |
GlobeNewswireGain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
Initiation of Phase 1b Study of GT-02287 in Parkinson’s patients expected by end of 2024BETHESDA, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the quarter ended September 30, 2024, and provides a corporate update. “The third quarter of 2024 marked substantial pro
- GlobeNewswire
Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
GT-03842, Identified by the Company’s Magellan Drug Discovery Platform, Effectively Hinders Phosphorylation and Activation of DDR2 GT-03842 May Offer Potential Favourable Therapeutic Attributes for Oncology Compared to Traditional Kinase Inhibitors BETHESDA, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therap
